Top Banner
www.csir.co.za © CSIR 2006 www.csir.co.za Polymeric shell Nanomedicine: An Innovative Approach Towards Treating Tuberculosis H. SWAI 1, L. KALOMBO, B. SEMETE and L. KATATA Encapsulation and Delivery Research Group Polymers and Composites, Materials Science and Manufacturing *E-mail: [email protected] , +27 12-841-2366
23

Nanomedicine: An Innovative Approach Towards Treating ... · Nanomedicine: An Innovative Approach Towards Treating Tuberculosis. H. SWAI. 1, L. KALOMBO, B. SEMETE and L. KATATA ...

Jul 10, 2019

Download

Documents

trankhuong
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Nanomedicine: An Innovative Approach Towards Treating ... · Nanomedicine: An Innovative Approach Towards Treating Tuberculosis. H. SWAI. 1, L. KALOMBO, B. SEMETE and L. KATATA ...

www.csir.co.za© CSIR 2006 www.csir.co.za

Polymericshell

Nanomedicine: An Innovative Approach Towards Treating Tuberculosis

H. SWAI1, L. KALOMBO, B. SEMETE and L. KATATA

Encapsulation and Delivery Research GroupPolymers and Composites,

Materials Science and Manufacturing *E-mail: [email protected], +27 12-841-2366

Page 2: Nanomedicine: An Innovative Approach Towards Treating ... · Nanomedicine: An Innovative Approach Towards Treating Tuberculosis. H. SWAI. 1, L. KALOMBO, B. SEMETE and L. KATATA ...

www.csir.co.za

TB: Prevalence in South AfricaSouth Africa TB StatisticsTB leading cause of death in SA

Highest infection rate in Africa

Fourth highest in the world

Due to:

Co-infection of HIV and TB in 80% of cases

Patients non compliance

Poor bioavailabilityTreatment period (6-9 months)

Dose and dose frequency

Adverse side effect

Hence

Multi-drug resistant TB (MDR-TB)

Extremely resistant TB (XDR-TB)

Page 3: Nanomedicine: An Innovative Approach Towards Treating ... · Nanomedicine: An Innovative Approach Towards Treating Tuberculosis. H. SWAI. 1, L. KALOMBO, B. SEMETE and L. KATATA ...

www.csir.co.za

Conventional Oral Delivery SystemLimiting factors for oral delivery• Gastric Intestinal Track (GIT):

• Harsh environment• Bioactives degradation• Poor permeability• Relatively short gastric

emptying and intestinal transit time

• Pre-systemic clearance

• Hence:• Poor bioavailability

• Increased dose & dose frequency

• Increased length of treatment• Drug toxicity• Drug-drug interaction

Page 4: Nanomedicine: An Innovative Approach Towards Treating ... · Nanomedicine: An Innovative Approach Towards Treating Tuberculosis. H. SWAI. 1, L. KALOMBO, B. SEMETE and L. KATATA ...

www.csir.co.za

Nano encapsulated TB drugs

Anti-TBdrugs

Polymericshell

INH-loaded PLGA nanoparticles

1 um

CLSM image of macrophage cell taken up 1 um size particles

200 nm

Page 5: Nanomedicine: An Innovative Approach Towards Treating ... · Nanomedicine: An Innovative Approach Towards Treating Tuberculosis. H. SWAI. 1, L. KALOMBO, B. SEMETE and L. KATATA ...

www.csir.co.za

Nanodrug delivery system in the GIT

Structure of the GIT Internal structure of the intestine

• Para-cellular via M cell

• Intracellular via epithelial cell-intestine mucosa

• Peyer's patches

Page 6: Nanomedicine: An Innovative Approach Towards Treating ... · Nanomedicine: An Innovative Approach Towards Treating Tuberculosis. H. SWAI. 1, L. KALOMBO, B. SEMETE and L. KATATA ...

www.csir.co.za

Routes and mechanisms of particle transport across epithelia

DC

UPTAKE via MALT

Lymph capillary

SER

OSA

L SI

DE

MU

CO

SAL

SID

E

mucus

Epithelial

cell

Celljunctio

n

ENDOCYTOSISby ordinary enterocytes

PARACELLULAR

LNBlood circulation

blood capillary

• Modified surface• Increase circulation time: PEG• Enhance particle uptake: Chitosan

Page 7: Nanomedicine: An Innovative Approach Towards Treating ... · Nanomedicine: An Innovative Approach Towards Treating Tuberculosis. H. SWAI. 1, L. KALOMBO, B. SEMETE and L. KATATA ...

www.csir.co.za

First pass metabolism 

Metabolism

AbsorptionDose

Excretion

Distribution 

Nanoparticle Transport

Roslyn Thelingwani

Spleen

Entry into lymphatic system

Page 8: Nanomedicine: An Innovative Approach Towards Treating ... · Nanomedicine: An Innovative Approach Towards Treating Tuberculosis. H. SWAI. 1, L. KALOMBO, B. SEMETE and L. KATATA ...

www.csir.co.za

Promises of Nano-drug delivery

• Enhance anti-TB drug properties• Solubility • Rate of dissolution: sustained and controlled release systems• Oral bioavailability: minimise first pass metabolism• Targeting ability

• Enhance anti-TB drug dosing requirements • Reduced dose and dose frequency• Minimal adverse side effects• Shortened treatment time • Improve patient compliance

• Generic (platform) technology • Anti-malarials• ARVs• Anti-cancer drugs• Long term pain killers• Traditional medicines

Page 9: Nanomedicine: An Innovative Approach Towards Treating ... · Nanomedicine: An Innovative Approach Towards Treating Tuberculosis. H. SWAI. 1, L. KALOMBO, B. SEMETE and L. KATATA ...

www.csir.co.za

Page 10: Nanomedicine: An Innovative Approach Towards Treating ... · Nanomedicine: An Innovative Approach Towards Treating Tuberculosis. H. SWAI. 1, L. KALOMBO, B. SEMETE and L. KATATA ...

www.csir.co.za

Proposed Solution

• Encapsulation of ATDs into multifunctional polymeric nanoparticles.

www.csir.co.za

Hydrophilic drug

Hydrophobic drug

Muco-adhesive ligand

Stealth coating

Targeting ligand

Schematic diagram of a multifunctional polymeric nanocarrier

Page 11: Nanomedicine: An Innovative Approach Towards Treating ... · Nanomedicine: An Innovative Approach Towards Treating Tuberculosis. H. SWAI. 1, L. KALOMBO, B. SEMETE and L. KATATA ...

www.csir.co.za

Project technical status

• Successfully nano encapsulated 4 of first line anti-TB drugs • Using double emulsion solvent evaporation - spray drying technique • PCT patent application filed

• Properties:• 200 nm average size• Highly reproducible production• Scalable (known pharmaceutical process equipment)• Narrow size distribution (polydispersity < 0.1)• Controllable surface charge• Modified surface

• Increase circulation time: PEG• Enhance particle uptake: Chitosan

• Developed other encapsulations systems• Natural polymers • Other synthetic polymers (Polycaprolactone)• Establishing a drug delivery platform

• ARVs• Malaria• Other PRD’s

Page 12: Nanomedicine: An Innovative Approach Towards Treating ... · Nanomedicine: An Innovative Approach Towards Treating Tuberculosis. H. SWAI. 1, L. KALOMBO, B. SEMETE and L. KATATA ...

www.csir.co.za

Encapsulation of all four drugs• Encapsulation of pre-formed drug-loaded micelle-like

containers

PLGA Nanocapsule

Page 13: Nanomedicine: An Innovative Approach Towards Treating ... · Nanomedicine: An Innovative Approach Towards Treating Tuberculosis. H. SWAI. 1, L. KALOMBO, B. SEMETE and L. KATATA ...

www.csir.co.za

In vitro uptake in CaCo-2 cells

Z-stack 30 min incubation 60 min incubation

Page 14: Nanomedicine: An Innovative Approach Towards Treating ... · Nanomedicine: An Innovative Approach Towards Treating Tuberculosis. H. SWAI. 1, L. KALOMBO, B. SEMETE and L. KATATA ...

www.csir.co.za

In vitro uptake in THP-1 cells

a) Coumarin labelled b) INH-PLGA

c) Rhodamine labelled

Page 15: Nanomedicine: An Innovative Approach Towards Treating ... · Nanomedicine: An Innovative Approach Towards Treating Tuberculosis. H. SWAI. 1, L. KALOMBO, B. SEMETE and L. KATATA ...

www.csir.co.za

Tissue distribution of Rhodamine labelled PLGA nanoparticles after 1 day exposure (CLSM images)

LUNGS LIVER KIDNEY

SPLEEN BRAIN HEART MUSCLES

Page 16: Nanomedicine: An Innovative Approach Towards Treating ... · Nanomedicine: An Innovative Approach Towards Treating Tuberculosis. H. SWAI. 1, L. KALOMBO, B. SEMETE and L. KATATA ...

www.csir.co.za

Tissue sections : High dose of PLGA particles

BRAIN

KIDNEY

HEART MUSCLES

LIVERLUNG

SPLEEN

Page 17: Nanomedicine: An Innovative Approach Towards Treating ... · Nanomedicine: An Innovative Approach Towards Treating Tuberculosis. H. SWAI. 1, L. KALOMBO, B. SEMETE and L. KATATA ...

www.csir.co.za

Release profile for free drugs vs encapsulated drugs: Improved formulation (Swai et al. unpublished data)

IN VIVO release

0.01

0.1

1

10

100

0 20 40 60 80 100 120 140 160

Hours

Con

c (u

g/m

l)

INH -2

INH-1

INH multi-drugs

Conv-INH

MIC-INH

RIF1

RIF2

Conv Rif

MIC-RIF

RIF Multidose

PZA1

PZA2

Conv-PZA

PZA Multidose

MIC-PZA

Page 18: Nanomedicine: An Innovative Approach Towards Treating ... · Nanomedicine: An Innovative Approach Towards Treating Tuberculosis. H. SWAI. 1, L. KALOMBO, B. SEMETE and L. KATATA ...

www.csir.co.za

Progress summary• Encapsulated 4 first line ATDs

• PCT patent filed- double emulsion SD technique • Micelles • Natural Polymers• 2 further invention disclosures

• In vitro assays • In vitro efficacy• In vitro stability and slow release profile• Particle uptake

• In vivo assays• Macrophage uptake• No abnormalities in tissues• No inflammatory response• Sustained release profile over 6 days

• Generic technology• Anti-retrovirals, antibiotics etc. • In search of collaborators in Malaria and traditional actives

Page 19: Nanomedicine: An Innovative Approach Towards Treating ... · Nanomedicine: An Innovative Approach Towards Treating Tuberculosis. H. SWAI. 1, L. KALOMBO, B. SEMETE and L. KATATA ...

www.csir.co.za

www.csir.co.za

Active targeted drug delivery

• Inherent macrophage mechanisms being manipulated- Phagocytosis and endocytosis- Over expression of protein in TB infected macrophages

• Direct mannose receptor mediated particle uptake• Novel technology• Aptamers against target protein• Preferential localization of particles

• Macrophage over expressing protein

• Mycolic acid• Cell wall of M.tb• Directing nanoparticles to M.tb in cells

Single stranded RNA

Folding

Incubation with target protein

Molecular complex

Page 20: Nanomedicine: An Innovative Approach Towards Treating ... · Nanomedicine: An Innovative Approach Towards Treating Tuberculosis. H. SWAI. 1, L. KALOMBO, B. SEMETE and L. KATATA ...

www.csir.co.za

Overview of drug delivery platform relationships & agreements

Page 21: Nanomedicine: An Innovative Approach Towards Treating ... · Nanomedicine: An Innovative Approach Towards Treating Tuberculosis. H. SWAI. 1, L. KALOMBO, B. SEMETE and L. KATATA ...

www.csir.co.za

Progress on HR Capacity Building• Recruitment progress

• 4 Post docs - Boitumelo Semete, Paul Chelule and Malebogo Legodi, Lebogang Katata

• 4 PhD students –Yolandy Benadie, Lonji Kalombo, Lindiwe Nkabinde and Laetitia Booysen

• 3 MSc students – Phumzile Hadebe, Saloshnee Naidoo and Trudy Maluleke• 4 Technikon students - Sonia Mathopo, Batabile Ramalapa and Koketso

Rapatla and Mofahloshi Chuene• Training completed (2006-2008)

• University of London, UK• EPFL, Switzerland • PGIMER, Chandigarh, India. • University of Nottingham, UK • University of Cardiff, UK• University of Liverpool, UK

• Training arranged for 2009 onwards• National Jewish Medical and Research Centre, USA • University of Nottingham, UK• University of London, UK• University of Colorado, USA

Page 22: Nanomedicine: An Innovative Approach Towards Treating ... · Nanomedicine: An Innovative Approach Towards Treating Tuberculosis. H. SWAI. 1, L. KALOMBO, B. SEMETE and L. KATATA ...

www.csir.co.za

THANK YOU

Page 23: Nanomedicine: An Innovative Approach Towards Treating ... · Nanomedicine: An Innovative Approach Towards Treating Tuberculosis. H. SWAI. 1, L. KALOMBO, B. SEMETE and L. KATATA ...

TB Nanodrug delivery Research Team - CSIR